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Introduction: The relationship between excision repair cross-com-
plementation group 1 (ERCC1) expression and outcome, in patients
with malignant pleural mesothelioma (MPM), treated with cisplatin/
vinorelbine combination-therapy, was retrospectively evaluated in a
patient population from a previously published phase II clinical trial.
Methods: The study population consisted of 54 inoperable patients
with MPM enrolled between 2003 and 2006. ERCC1 expression was
evaluated by immunohistochemistry (IHC) on the formalin-fixed
paraffin-embedded diagnostic biopsies. The immunoreaction was
quantified using an H-score (staining intensity multiplied by a
proportion score based on the percentage of stained tumor cells).
The cutoff point was chosen as the median H-score in a cohort of
non-neoplastic pleural samples from patients with benign thoracic
diseases. The tumor samples were separated according to this cutoff
point into ERCC1-negative (H-score  median) and ERCC1-posi-
tive (H-score  median) cases.
Results: Fifty patients had tumor tissue available for IHC. There
were 20 ERCC1-positive and 30 ERCC1-negative tumors. There
was a significant correlation between negative ERCC1 status and
long progression-free survival (PFS). Median PFS was 10.9 months
in the ERCC1-negative group, opposed to 6.7 months in the
ERCC1-positive group (p  0.053). Multivariate Cox regression
showed ERCC1 to be the only variable significantly associated with
PFS, and ERCC1-positive patients had a significantly shorter time to
progression compared with ERCC1-negative patients (hazard ratios,
2.24; 95% confidence interval, 1.16–4.34; p  0.0163). We found
no association between ERCC1 status and overall survival.
Conclusion: Our retrospective study in MPM patients treated
with cisplatin/vinorelbine suggests that low ERCC1 expression,
evaluated by IHC, may predict longer PFS, a result that warrants
further validation.
(J Thorac Oncol. 2012;7: 249–256)
Malignant pleural mesothelioma (MPM) arises from themesothelium lining the pleural cavity, and development of
this cancer is often associated with previous asbestos exposure.
Because of the long tumor latency, the incidence of MPM is
increasing, despite the ban issued on asbestos use 3 decades
ago.1 MPM has a poor prognosis in advanced disease, and only
a small minority of patients is diagnosed at an early stage, when
curative multimodality treatment is possible. Inoperable patients
are usually offered a two-drug platinum-based chemotherapy
regimen.2 Platinum compounds are used in the treatment of a
large variety of cancers, but their efficacy is often limited by the
intrinsic or acquired resistance of the cancer cells toward their
mechanism of action.3,4
The last few years have witnessed an increased focus
on markers of resistance, which can be used to predict
treatment efficacy and thereby guide treatment decisions.
Cisplatin and carboplatin work by binding to the DNA
forming adducts that lead to intra- or interstrand cross-links.
The formation of these DNA cross-links inhibits the cell from
replicating and drives it toward apoptosis. This proapoptotic
signal can be counteracted by the cells’ intrinsic ability to
recognize and repair the DNA damage. Nucleotide excision
repair is a highly conserved pathway that maintains DNA
integrity by removing helix-distorting cross-links. This path-
way seems to be a key element in mediating resistance toward
platinum compounds. There are three important steps in this
pathway. First, the DNA damage is recognized then excised,
and finally, the excised area is resynthesized. Excision repair
cross-complementation group 1 enzyme (ERCC1), a protein
encoded by a gene located on chromosome 19q plays a
rate-limiting step in this process by forming a complex with
xeroderma pigmentosum complementation group F that ex-
cises the damaged DNA.3–5
An inverse relationship between ERCC1 mRNA lev-
els and response to cisplatin-based therapy has been shown
in several retrospective studies on tumor samples from
clinical trials with ovarian cancer,6,7 colorectal cancer,8,9
and non-small cell lung cancer (NSCLC).10 Olaussen et
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al.11 subsequently published a retrospective study on the
immunohistochemical determination of ERCC1 status in a
large randomized trial, among completely resected NSCLC
patients, randomized to receive cisplatin-based adjuvant che-
motherapy or not. They reported an increased therapeutic
benefit for patients with low ERCC1 expression, and also
observed high ERCC1 expression to be a marker of good
prognosis in the patient group not receiving adjuvant cispla-
tin, possibly due to a more efficient DNA repair and conse-
quently fewer genetic abnormalities during tumor progres-
sion. The same methodology has more recently been used by
Vilmar et al.12 in a retrospective study to test the association
of ERCC1 expression with response to cisplatin therapy in
the palliative setting in advanced NSCLC. Again, a better
treatment response was seen in the ERCC1-negative tumor
population.
Two studies have recently addressed the possible pre-
dictive and prognostic role of ERCC1 in MPM. In an obser-
vational study by Righi et al.,13 immunohistochemistry
(IHC)was used to detect ERCC1 in a cohort of 45 MPMs
treated with different platinum-based therapies (cisplatin 
pemetrexed or carboplatin  pemetrexed in different regi-
mens). In this series, there was no association between
ERCC1 status and treatment response, but the authors did
find high ERCC1 levels to be associated with a better prog-
nosis regardless of the chemotherapy regimen used. More
recently, Zucali et al.14 also used IHC to detect ERCC1 in a
retrospective cohort of 67 MPMs treated with a combination
of pemetrexed and carboplatin. Moreover, these authors
found no association between ERCC1 protein status and
clinical outcome in terms of disease control, progression-free
survival (PFS) and overall survival (OS).
The aim of our study was to investigate the potential
role of ERCC1 protein status as a predictive marker for
efficacy of cisplatin-based chemotherapy in MPM. For this
purpose, we used immunohistochemical analysis to detect
ERCC1 protein expression on diagnostic tissue samples, from
inoperable patients, treated uniformly with a combination of
cisplatin and vinorelbine, in a previously reported phase II
clinical trial.15
PATIENTS AND METHODS
Patient Population
The study population consisted of 54 consecutive in-
operable patients enrolled into a phase II trial conducted at
our institution between 2003 and 2006.15 Eligibility criteria
were as follows: Histologically verified MPM judged to be
inoperable because of age 70 years, anatomical extension
of disease (N2/N3 nodal status), nonepitheloid histology, or
physiological inoperability (poor cardiopulmonary function,
etc.). Patients were required to have measurable disease;
Eastern Cooperative Oncology Group performance status
0–2; an estimated survival expectancy 3 months; age 18
years and had given informed written consent. Treatment was
vinorelbine 25 mg m2 intravenously weekly and cisplatin
100 mg m2 intravenously every 4 weeks. Staging was done
according to the system defined by the International Meso-
thelioma Interest Group.16
Response Evaluation
Patients were assessed with spiral computed tomo-
graphic scans at baseline before every other treatment cycle
(every 8 weeks) and every 2 months after treatment comple-
tion. Treatment response was assessed by modified RECIST
criteria.17 Change in disease was assessed by measuring
tumor thickness perpendicular to the chest wall or mediasti-
num in up to three involved areas at least 2 cm apart. A
reduction of at least 30% or an increase of 20% on two
occasions 4 weeks apart was defined as a partial response
(PR) or progressive disease (PD), respectively. A complete
response (CR) was defined as complete absence of signs and
symptoms of disease. In case of patients having not evaluable
disease, progression (PD) was defined as the appearance of a
new disease parameter. Response rate (RR) was defined as
the proportion of patients, having evaluable disease, who
achieved a CR or PR. The primary endpoint was PFS, defined
as time from onset of treatment until documented progression
or death from any cause, because this is an established marker
of treatment efficacy in MPM supported by the European
Organisation for Research and Treatment of Cancer.18 For
patients not evaluable by modified RECIST criteria, PFS was
calculated from onset of treatment until the appearance of a
new disease parameter or death. OS was the time from
initiation of treatment until death from any cause. For patients
without progression at the time of analysis, OS and PFS were
censored at the date of the last follow-up.
Tissue Samples
The formalin-fixed paraffin-embedded (FFPE) bioptic
tumor specimens from the enrolled patients were obtained
from Departments of Pathology throughout Denmark. Hema-
toxylin and eosin-stained sections from each specimen were
reviewed by three independent observers (Z.G.Z., E.S.-R.,
and C.B.A.), to confirm the diagnosis and evaluate the suit-
ability of the samples for the immunohistochemical analysis.
Immunohistochemistry
Thin (2 ) sections were cut from each biopsy and
mounted on coated glass slides. Sections were deparaffinized,
and heat-induced antigen retrieval was performed in DAKO-
PT-link module using target retrieval solution pH9 for 20
minutes at 97°C (DAKO, Glostrup, Denmark). Endogenous
peroxidase was blocked, and sections were incubated at room
temperature for 20 minutes with mouse monoclonal antihu-
man ERCC1 Ab-2 (clone 8F1; Thermo Fisher Scientific,
Freemont, CA) diluted 1:200. Staining was visualized with
EnVision flex  kit (DAKO) with diaminobenzidine as
chromogen, and the sections were then counterstained with
Meyer’s hematoxylin for 1 minute. The immunostaining was
carried out using DakoAutostainer PLUS.
Controls
Background staining was evaluated by omitting the
primary antibody, in which case no staining was observed.
Sections from two FFPE glioblastoma multiforme, known to
have loss-of-heterozygosity at the 19q locus, served as neg-
ative controls and showed only weak nuclear staining in
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single sporadic tumor cells. FFPE cell pellets from the ovar-
ian cancer cell line A2780 served as a positive control19
(provided by N.Z. Sroczynski, TopoTarget, Copenhagen,
Denmark). The cell pellet showed moderate nuclear staining.
Controls are shown in Figure 1 A, B.
Immunostaining Evaluation
The staining was separately evaluated by two indepen-
dent observers (Z.G.Z., and E.S.-R.) blinded to the clinical
data. In discordant cases, consensus was reached by the use of
a two-headed microscope. ERCC1 nuclear staining was as-
sessed using a semi-quantitative H-score as previously de-
scribed.11,12 Briefly, staining intensity was evaluated against a
positive control and assigned a value between 0 and 3 (0 
no staining, 1  control, 2  control, and 3  control).
Lymph node endothelium stained along with the tumor spec-
imens served as an external control with staining intensity 2
(Figure 1C), and tumor vessels were used as internal controls.
The percentage of positive tumor cells were evaluated and a
proportion score assigned (0.1  10%, 0. 5  10–50%, 1 
50%). The proportion score was determinate by counting at
least 500 cells per sample. The final H-score was calculated
by multiplying the staining intensity by the proportion score.
To establish a reference range, we examined the staining
pattern of mesothelium in a cohort of FFPE non-neoplastic
pleural samples (n  34) from patients with benign thoracic
diseases. The cutoff point was then chosen as the median
H-score in this cohort to separate ERCC1-positive
(H-score  median) from ERCC1-negative (H-score  me-
dian) tumor samples.
Statistical Analysis
Categorical variables were compared by Fisher’s exact
test. Survival curves for OS and PFS were obtained with the
Kaplan-Meier method. Multivariate Cox regression was used
to analyze OS and to investigate the association of ERCC1
status with PFS adjusting for the following known risk
factors: patient’s age and gender, tumor histology (epitheliod
versus nonepitheliod), performance status (Eastern Coopera-
tive Oncology Group performance-status score 0, 1, or 2),
and disease stage (Ia/Ib/II, III, or IV). Results are presented as
hazard ratios (HR) with 95% confidence intervals (CIs).
FIGURE 1. ERCC1 immunoreac-
tions in different representative tis-
sue sections. A, Glioblastoma multi-
forme with known loss-of-
heterozygosity at the 19q locus
served as negative control. Note
only sporadic positive nuclei. B,
Ovarian cancer cell line A2780
served as positive control and
showed moderate nuclear staining.
C, Lymph node endothelium was
used as an intensity reference and
assigned an intensity score of 2. D,
ERCC1 in normal pleura from a pa-
tient with cystic fibrosis showing
mild mesothelial hyperplasia with
an H-score of 2. E, ERCC1-negative
MPM with an H-score of 0.5. F,
ERCC1-positive MPM with an H-
score of 3.
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Time-dependent sensitivity and specificity were computed for
the PFS status when predicted by patients’ ERCC1 status
alone and supplied with exact binomial 95% CIs at each
time-point. Progression before time t is regarded as a positive
response and disease control until time t is regarded as a
negative response for the computation of the diagnostic
performance of the marker. Thus, in our setting, the true
positive rate (TPR), or sensitivity, is the probability of a
patient being ERCC1 positive given progression by time t.
Correspondingly, the true negative rate (TNR), or specificity,
is the probability of a patient being ERCC1 negative given he
or she is progression-free until time t.
RESULTS
Patient Characteristics
Fifty-four consecutive inoperable patients with MPM
were enrolled between February 2003 and September 2006.
Treatment results and patient characteristics were described
in detail by Sørensen et al.15 and briefly summarized in Table
1. The FFPE diagnostic tumor tissue was available from 50
patients (93%). Patients were predominantly male (84%) with
epitheloid histology (78%), performance status (PS) 0–1
(94%), and International Mesothelioma Interest Group stages
III and IV (80%). Median age was 64 years (range, 31–78
years). On progression, 22 patients (44%) received pem-
etrexed as second-line treatment. All patients, except two,
died during the follow-up period. One had a CR and the OS
and PFS times were censored at 77 months. Another patient
had a PR but progressed after 40 months and received
second-line pemetrexed, the OS time was censored after 44
months.
Immunohistochemical Evaluation of ERCC1 Status
The cohort of non-neoplastic pleura, used to establish
the normal reference range, consisted of 34 samples. Twenty-
seven were lung resections from patients with relapsing
pneumothorax, which showed reactive mesothelium hyper-
plasia. Seven were pleura-covered lung-tissue sections from
patients undergoing lung transplantation because of cystic
fibrosis. The median H-score was 2 (lower quartile, 2; upper
quartile, 2) and this was then set as the cutoff point. A
representative example of ERCC1 immunostaining in the
mesothelium of a patient with cystic fibrosis is shown in
Figure 1D.
The tumor cohort showed a wider range of H-scores,
but here the median H-score was also 2 (lower quartile, 2;
upper quartile, 3). The previously established cutoff point
separated the tumor samples into 20 positives (H-score 2)
and 30 negatives (H-score 2). Representative samples of
ERCC1-positive and -negative MPMs are illustrated in Fig-
ure 1E, F. Demographics and tumor characteristics of patients
being ERCC1 positive or ERCC1 negative were comparable
with respect to the distribution of gender, age, stage, and
histology (p  0.05). Only three patients in the study-
population had PS 2 and they were all ERCC1 positive (p 
0.008). The demographics and tumor characteristics of the
study population according to ERCC1 status are shown in
Table 1.
Survival and ERCC1 Expression
The median OS in the study population was 16.8
months (95% CI, 12.5–18.6 months) (Table 1 and Figure 2
A). There was no significant difference in OS between
ERCC1-positive and -negative patients (HR, 1.29; 95% CI,
0.7–2.36; p  0.4) (Figure 2). Multivariate Cox regression
showed a significant association between PS and OS (HR,
2.15; 95% CI, 1.04–4.42; p  0.03). The remaining factors
did not show a significant association to OS (p  0.05) (see
Table 2).
TABLE 1. Demographics and Tumor Characteristics of the
Study Population According to ERCC1 Status
Demographics According
to ERCC1 Status
ERCC1
Negative
(N  30)
ERCC1
Positive
(N  20)
Total
(N  50) p
Gender
Female 5 3 8 1
Male 25 17 42
Age (yr)
Median 64 64 64 0.9
Range 31–77 40–78 31–78
IMIG stage
Ia 1 0 1 0.8
Ib 0 1 1
II 4 4 8
III 11 7 18
IV 14 8 22
Performance status
0 6 6 12 0.008
1 24 11 35
2 0 3 3
Histology
Epitheloid 22 17 39 0.7
Biphasic 7 3 10
Sarcomatoid 1 0 1
Response
CR 2 0 2 0.7
PR 7 6 13
SD 16 9 25
PD 1 1 2
NE 4 4 8
RR 35% 37.5% 35.7%
Poststudy treatment
Number 10 11 22 0.2
Events
Death 28 20 48 0.5
Alive 2 0 2
PFS (mo)
Median 10.9 6.7 6.7 0.053
Range 1.8–76.8 1.4–48.1 1.4–76.8
OS (mo)
Median 16.5 17.4 16.8 0.37
Range 4.7–79.6 1.3–48.3 1.3–79.6
ERCC1, excision repair cross-complementation group 1; IMIG, International Me-
sothelioma Interest Group; CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease; NE, not evaluable; RR, response rate; PFS, progres-
sion-free survival; OS, overall survival.
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Treatment Efficiency and ERCC1 Expression
The overall RR in the study population was 35.7%, and
there was no significant difference between RR when patients
were grouped by ERCC1 status (p  0.7) (Table 1). The
median PFS, however, was 10.9 months (95% CI, 5.6–16.7
months) in the ERCC1-negative tumor group and 6.7 months
(95% CI, 4.4 –7.2 months) in the ERCC1-positive group
(p  0.053) (Table 1 and Figure 2B). Multivariate Cox
regression showed that the ERCC1-positive patients had a
significantly shorter time to progression or death (HR,
2.24; 95% CI, 1.16–4.34; p  0.0163) compared with
ERCC1-negative patients (Table 3). The remaining factors
(age, gender, histological subtype, stage, and PS) were not
significant (p  0.05).
Predictive Value of ERCC1 Expression
Figure 3 shows time-dependent sensitivity and speci-
ficity for predicting patients’ PFS-status based on ERCC1.
The figure shows sensitivity of ERCC1 below 50% during the
whole study period. The specificity, however, is high during
the first 3 years. Taken together, these results indicate that
patients who experience long-term disease control (implying
treatment benefit) are more likely to be ERCC1 negative.
DISCUSSION
The evidence to support the role of ERCC1 as a
marker of cisplatin sensitivity in various cancer types is
growing. The clinical utility of this biomarker to guide
treatment decisions is currently being addressed in pro-
TABLE 2. Cox Regression Results for Overall Survival
Factor HR 95% CI p
Age 1.00 0.97–1.03 0.9181
Gender 2.28 0.98–5.31 0.0552
Nonepitheloid histology 0.64 0.27–1.54 0.3202
Stage III 0.87 0.35–2.17 0.7679
Stage IV 1.00 0.44–2.26 0.9930
Performance status 2.15 1.04–4.42 0.0383
ERCC1 status 1.29 0.70–2.36 0.4138
Age and performance status are continuous variables, gender and ERCC1 status are
binary, nonepitheloid histology is compared with epitheloid histology, and stage III and
IV are compared with stages Ia/Ib/II.
HR, hazard ratios; CI, confidence interval; ERCC1, excision repair cross-comple-
mentation group 1.
TABLE 3. Cox Regression Results for Progression-Free
Survival
Factor HR 95% CI p
Age 0.97 0.94–1.01 0.1195
Gender 1.85 0.79–4.34 0.1575
Nonepitheloid histology 1.10 0.49–2.45 0.8172
Stage III 0.79 0.30–2.04 0.6209
Stage IV 0.94 0.41–2.16 0.8852
Performance status 1.80 0.89–3.63 0.1038
ERCC1 status 2.24 1.16–4.34 0.0163
Age and performance-status are continuous variables, gender and ERCC1 status are
binary, nonepitheloid histology is compared with epitheloid histology, and stage III and
IV are compared with stages Ia/Ib/II.
HR, hazard ratios; CI, confidence interval; ERCC1, excision repair cross-comple-
mentation group 1.
FIGURE 2. A, Kaplan-Meier curves showing overall survival
according to ERCC1 status with 95% confidence intervals (CIs)
(gray shades), p  0.37. The number of patients in the study
at different time-points is indicated below the figure. B, Kaplan-
Meier curves showing progression-free survival probabilities by
ERCC1 status with 95% CIs (gray shades), p  0.053. The
numbers of patients at risk are indicated below the figure.
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spective randomized trials, e.g., in NSCLC and epithelial
ovarian cancer (clinical trials.gov). The impact of ERCC1
expression on treatment response and prognosis in MPM is
not yet well established, and only two previous studies
addressing this issue have been published.13,14 Our study
aimed at exploring the role of ERCC1 as a predictive
biomarker in a well defined and uniformly treated patient
population. We chose to evaluate ERCC1 status by IHC
because this technique is fast, cheap, and easily applicable
to routinely collected histological specimens. We have
used the same 8F1 anti-ERCC1 antibody that has been
used in several recent publications describing the predic-
tive value of ERCC1 in other human cancer types.11–13,20,21
On the basis of antibody evaluation performed in cultured
cell lines, Bhagwat et al.22 have raised concern about the
specificity of the 8F1 antibody, but this has later been
efficiently rebutted by a specific validation of the 8F1
antibody in human cancer cell lines and FFPE NSCLC
tissue sections.23 We have tried to take this issue into
account by performing relevant controls. As the ERCC1
gene is located on chromosome 19q, we use as a negative
control, FFPE tumor samples from two patients with gli-
oblastoma multiforme, with LOH at the 19q locus, col-
lected and investigated for 19q deletion as part of routine
histopathological practice. In these specimens, we saw
nuclear positivity in the endothelium and lymphocytes, but
most of tumor cells were ERCC1 negative with only few
occasional positive tumor cells, as could be expected due
to tumor cell heterogeneity. As a positive control, we used
a FFPE cell pellet from the ovarian cancer cell line A2780,
known to express ERCC1. Here, we saw a moderate
nuclear staining intensity. On the basis of these controls,
we conclude that the antibody is specific for ERCC1.
We found no correlation between ERCC1 status and
objective treatment response evaluated by the modified
RECIST criteria applicable to MPM. No difference in OS
based on ERCC1 status was seen. Nevertheless, we did find
low ERCC1 expression to correlate with longer PFS and a
multivariate analysis of PFS-yielded ERCC1 status as the
only variable significantly influencing PFS. We also report
the time-dependent sensitivity and specificity of ERCC1. Our
analysis indicates that ERCC1 status could potentially be
useful for discriminating patients with expected long-term
disease control from patients with expected early progression,
but this requires further validation.
What we observed was a stabilization of disease in
terms of longer PFS in the patient group with low ERCC1
expression. The median PFS in the ERCC1-negative group
was 10.9 versus 6.7 months in the ERCC1-positive group. A
4-month increase in PFS seems a relevant difference for a
relentlessly PD with a short life expectancy. Unfortunately,
this difference in PFS did not translate into an OS advantage
because the OS in the ERCC1-positive group was 17.4
months opposed to 16.5 months in the ERCC1-negative
group. It has been suggested that high ERCC1 expression is
associated with a better prognosis in untreated NSCLC,
possibly because tumors with more efficient DNA repair
accumulate less DNA aberration.11 The difference in OS in
our study is not statistically significant, and so we hesitate to
believe that the results reflect a truly opposite effect of
ERCC1 on OS and PFS, respectively. One reason why we do
not see an OS difference between ERCC1-positive and -neg-
ative groups might be that on tumor progression, 44% of the
study population received pemetrexed as second-line therapy,
which might have affected OS and even obscured the effect
of ERCC1 on OS.
Our results support the hypothesis that ERCC1 is in-
deed a marker of cisplatin resistance in MPM. These results
may motivate further and larger studies of the predictive
utility of ERCC1 as a guide to individualized and optimized
treatment. Our study results are consistent with those from
similar studies in other cancer types, showing increased
benefit from cisplatin-based therapy in patients having
ERCC1-negative tumors.
The other published studies on ERCC1 expression in
MPM13,14 did not report an association between ERCC1
expression and time-to-progression or PFS after platinum-
based palliative chemotherapy. A possible reason for the
discrepancy between these results and our own findings might
be that all patients in the study by Zucali et al.14 and
approximately half the patients in the study by Righi et al.13
were treated with carboplatin-based therapy instead of cis-
platin, which is used in our study population. There is no
preclinical data suggesting different mechanisms of resis-
tance among platinum compounds, but the influence of
ERCC1 on the action of carboplatin, in the clinical setting,
FIGURE 3. Time-dependent true positive and true negative
rates (%) for predicting patient’s progression-free survival
status based on ERCC1. The true positive rate (TPR) is the
probability of a patient being ERCC1 positive given he or
she has progressed at time t. The true negative rate (TNR) is
the probability of a patient being ERCC1 negative given he
or she is progression-free at time t.
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is less well explored, and varying results have been ob-
served.24 The fact that both previous studies13,14 used
pemetrexed as first-line treatment might also influence the
impact of ERCC1 on PFS.
Righi et al.13 identified a significant lower OS in pa-
tients having very low expression of ERCC1, when ERCC1
expression was dichotomized using a data-dependent cutoff
value (tertile). Such findings could, however, not be repro-
duced in our data. In the study by Righi et al., the difference
in OS, according to ERCC1, occurs at 16 to 18 months after
initiation of therapy. One reason why we cannot see the same
OS difference might be that 44% of our cohort received
second-line treatment (22 patients received poststudy pem-
etrexed), this might affect and even obscure the effect of
ERCC1 on OS.
Both previous studies used the same 8F1 antibody as
we use, but the H-score used to evaluate the staining was
slightly different from ours as the percentage of positive
tumor cells was assigned a continuous score instead of the
categorical score we use. This might be another reason for
the differences between results highlighting a well-known
problem with the quantitative evaluation of IHC. Even
when using a semi-quantitative H-score relying on formal
criteria and internal controls, this technique is still subject
to interobserver and interlaboratory variability. This prob-
lem can perhaps be circumvented in the future by using
newer techniques like Automated Quantitative Analysis
(AQUA technology; HistoRx Inc., New Haven, Conneti-
cut), a fluorescence-based method that provides objective
and continuous protein expression scores in tissues using
automated fluorescence microscopy and image analysis
software.25,26
In our study and in the two previous ones, an intensely
positive ERCC1 expression in the non-neoplastic pleura and
in most of the tested MPM cases was observed. This could
suggest that one of the reasons for the common resistance
toward platinum-based chemotherapy, seen in MPM, might
reside in the intrinsic ability of mesothelium cells to express
high levels of ERCC1.
Our study used archival samples from a prospective,
uniformly treated cohort but the study was not originally
designed to address the medical utility of this marker in
guiding treatment decisions. Nevertheless, because this is to
the best of our knowledge the first report on ERCC1 expres-
sion in a prospective, uniformly treated MPM cohort, we
believe our data can further contribute to establish the clinical
validity of this marker in the treatment of MPM. Further
studies are of course required to validate our findings and
establish the clinical utility of ERCC1 in guiding treatment
choices in patients with MPM.
CONCLUSION
Immunohistochemical evaluation of ERCC1 expres-
sion in pretreatment diagnostic pleural biopsies from inoper-
able MPM patients is feasible and reveals that low ERCC1
expression may predict longer PFS in patients treated with
cisplatin-based chemotherapy. These results should be further
validated in subsequent studies for confirmation or refutation
as false positive. If they are confirmed, these findings may
find use in the planning of future customized treatments of
MPM, a disease in which better treatment options are ur-
gently needed.
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